Xinyuan Meng

Incidence, Management, and Clinical Outcomes of Cardiovascular Adverse Events in Patients Receiving ALK Inhibitors for Advanced Non-Small Cell Lung Cancer: A Real-World Single-Center Analysis

Cardiovascular adverse event (CVAE) profiles across ALK-TKI generations remain incompletely characterized in real-world practice. A retrospective study of 235 ALK-rearranged NSCLC patients receiving first-, second-, or third-generation ALK-TKIs assessed CVAE incidence, severity,...